FibroBiologics Stock (NASDAQ:FBLG)
Previous Close
$0.33
52W Range
$0.28 - $2.98
50D Avg
$0.45
200D Avg
$0.78
Market Cap
$14.44M
Avg Vol (3M)
$875.29K
Beta
-0.70
Div Yield
-
FBLG Company Profile
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.